PAHO’s Revolving Funds Deliver Critical Health Supplies to the Americas
Washington D.C., February 19, 2026 – The Pan American Health Organization’s (PAHO) Regional Revolving Funds (RFF) delivered over 234 million vaccine doses and 13 million diagnostic tests to countries across the Americas in 2025. These supplies reached an estimated 85 million people, aiding in the prevention of outbreaks, vaccine-preventable diseases, and avoidable deaths.
Affordable Access to Essential Health Supplies
Through pooled procurement mechanisms, countries secured over US$900 million in health supplies at affordable prices, often realizing savings of around 50% on many public health essentials. This allows nations to maximize limited health budgets and ensure timely access to critical resources, particularly during emergencies.
PAHO Director Highlights Collaborative Efforts
“The Regional Revolving Funds continue to adapt to the evolving needs of our Member States, making cutting-edge vaccines, treatments, and diagnostics more accessible and affordable,” said PAHO Director Dr. Jarbas Barbosa. “By working together, countries strengthen supply security, reduce dependency on external sources, and advance disease prevention and elimination for all.”
Broad Regional Reach
Nearly every country and territory in the Americas – with the exception of Canada and the United States – along with nine Caribbean territories, two subnational entities, and seven public institutions, accessed supplies through the Funds.
Boosting Regional Manufacturing
A significant achievement in 2025 was the region’s progress in local manufacturing. Long-term agreements established in recent years have increased regional production from 1.5% of RRF procurement in 2020 to 23%, with capacity expected to reach 40% in the near term. This shift aims to strengthen supply security and reduce reliance on external manufacturers and potential global supply disruptions.
Expanded Product Availability
Countries also expanded their use of new products made available through the Funds, including:
- Malaria treatments and testing
- Telehealth devices
- Dengue and RSV vaccines
- The 9-valent HPV vaccine for cervical cancer prevention
- An increased selection of high-cost medicines and pediatric cancer treatments
- New diagnostics and treatments for advanced HIV disease and tuberculosis
Rapid Response and Cost Savings
New supply arrangements allowed PAHO to reserve doses in advance, supporting rapid action during yellow fever and measles outbreaks. Procurement of high-cost medicines also generated substantial savings, with negotiated agreements offering up to 90% reductions for treatments for breast cancer, prostate cancer, multiple sclerosis, and Gaucher disease.
Increased Demand for Key Initiatives
Demand for health supplies connected to PAHO’s Elimination Initiative grew significantly, with a 20% increase in HIV and viral hepatitis diagnostic tests and 10 million additional malaria tests, doubling the 2024 volume.
Investment in Essential Equipment
Twelve countries procured essential equipment through the mechanism, including maternal and neonatal technologies, ambulances, cold-chain systems, TB diagnostic machines, cardiovascular devices, and cervical cancer screening and treatment tools, as well as telehealth devices.
Digital Efficiency Improvements
The Funds’ efficiency continued to improve through the digital Member States Portal, which now has more than 530 users from ministries of health and processed over 200 country demand plans, a 30% increase from 2024.
About the PAHO Regional Revolving Funds
The PAHO Regional Revolving Funds – comprising the Revolving Fund for Access to Vaccines (operating for more than 40 years) and the Strategic Fund for Public Health Supplies – are technical cooperation mechanisms that pool demand, leverage economies of scale, and negotiate transparently with suppliers. This approach lowers costs, strengthens national immunization and health programs, and supports disease control, elimination, and emergency response across the Americas.